scholarly journals Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (27) ◽  
pp. 44490-44497 ◽  
Author(s):  
Kan Zhai ◽  
Yong Yang ◽  
Zhi-Gang Gao ◽  
Jie Ding
Keyword(s):  
Interleukin 6 ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Patients With Cancer ◽  
Gene Promoter Polymorphism

-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis

2012 ◽  
Vol 33 (6) ◽  
pp. 1481-1486 ◽  
Author(s):  
Ivan Jančić ◽  
Nevena Arsenović-Ranin ◽  
Mirjana Šefik-Bukilica ◽  
Sladjana Živojinović ◽  
Nemanja Damjanov ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interleukin 6 ◽  
Therapeutic Response ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Gene Promoter Polymorphism

scholarly journals An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women

2013 ◽  
Vol 30 (12) ◽  
pp. 1541-1546 ◽  
Author(s):  
Venkat Reddy Tumu ◽  
Suresh Govatati ◽  
Praveen Guruvaiah ◽  
Mamata Deenadayal ◽  
Sisinthy Shivaji ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Interleukin 6 ◽  
Polycystic Ovary ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Ovary Syndrome ◽  
Indian Women ◽  
South Indian ◽  
Gene Promoter Polymorphism

scholarly journals Impact of Interleukin-6 –174 G>C Gene Promoter Polymorphism on Neuroblastoma

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e76810 ◽  
Author(s):  
Francesca Totaro ◽  
Flora Cimmino ◽  
Piero Pignataro ◽  
Giovanni Acierno ◽  
Marilena De Mariano ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Gene Promoter Polymorphism

Associations of the −174 G/C Interleukin-6 Gene Promoter Polymorphism with Serum Interleukin 6 and Mortality in the Elderly

2005 ◽  
Vol 6 (6) ◽  
pp. 415-423 ◽  
Author(s):  
Giovanni Ravaglia ◽  
Paola Forti ◽  
Fabiola Maioli ◽  
Martina Chiappelli ◽  
Paolo Dolzani ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Gene Promoter ◽  
The Elderly ◽  
Promoter Polymorphism ◽  
Gene Promoter Polymorphism

P1-297: Interleukin-6 gene promoter polymorphism in Alzheimer's disease patients

2006 ◽  
Vol 2 ◽  
pp. S183-S184
Author(s):  
Spencer L.M. Payão ◽  
Fabio A.F. Barbosa ◽  
Roger W. de Labio ◽  
Luciano L. Gatti ◽  
Thaı́s Minett ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Interleukin 6 ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Gene Promoter Polymorphism

A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome

2004 ◽  
Vol 81 (6) ◽  
pp. 1638-1641 ◽  
Author(s):  
Katharina Walch ◽  
Christoph Grimm ◽  
Robert Zeillinger ◽  
Johannes C Huber ◽  
Friedrich Nagele ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Interleukin 6 ◽  
Clinical Characteristics ◽  
Polycystic Ovary ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Ovary Syndrome ◽  
Gene Promoter Polymorphism

scholarly journals Impact of Interleukin-6 and Interleukin-10 Gene Polymorphisms on Inhibitor Development in Patients with Moderate and Severe Hemophilia a

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5026-5026
Author(s):  
Hoda Hassab ◽  
Marwa Hanafi ◽  
Ahmed Abdelmaksoud ◽  
Shimaa ElSayed
Keyword(s):  
Factor Viii ◽  
Interleukin 6 ◽  
Hemophilia A ◽  
Gene Promoter ◽  
Human Leukocyte ◽  
Interleukin 10 ◽  
Promoter Polymorphism ◽  
P Value ◽  
Severe Hemophilia ◽  
Gene Promoter Polymorphism

Abstract Background: An important complication of administration of factor VIII concentrates to treat or prevent bleeding,is the development of autoantibodies that block the activity of the relevant factor (inhibitors). These inhibitory antibodies occur in approximately 25 % of patients with severe hemophilia A. Inhibitors are much less common in patients with mild or moderate disease. Recently, significant progress has been made in our understanding of the mechanisms that lead to inhibitor formation. Polymorphisms of the immune response genes have been suggested to be contributing determinants of the inhibitor risk. Previous immunogenetic studies have shown the implication of human leukocyte antigen (HLA) alleles and some of the cytokine polymorphisms in inhibitors formation such as IL-6 and IL-10. Aim: This study aimed to investigate the associations between interleukin-6 gene promoter polymorphism at position (−174 G/C), interleukin-10 gene promoter polymorphism at position (-1082G/A) and susceptibility of patients with hemophilia A to develop factor VIII inhibitors. Methods and subjects: After medical ethical committee approval, the present study was conducted on 50moderate and severehemophilia A males aged ≤ 18 years who are attending hematology outpatient clinic of Alexandria University Children's Hospital at El-Shatby. The 50 children were undergoing a)Detailed history taking, with special emphasis on: Age of the patient at the time of diagnosis, clotting activity of factor VIII, Age at first exposure to factor VIII, Type and dose of administered factor VIII concentrate. Exposure days (EDs), Age at first surgical intervention, Detection of factor VIII inhibitors b)Laboratory investigations: Identification of genetic variant IL-6 (rs1800795) , IL-10 ( rs1800896 ) using real time PCR. Results: Thirtyone (72.1%) patients had severe hemophilia and 19 (27.9%) had moderate Hemophilia. Eight (16%) of the studied patients were inhibitor positive. As regard interleukin-6 gene promoter polymorphism at position (−174 G/C), the frequency of G allele was greater than C allele in patients who developed inhibitors (χ2= 0.63) with P value = 1.000. regarding interleukin-10 gene promoter polymorphism at position (-1082G/A), the frequency of G allele was greater than A allele in patients who developed inhibitors (χ20.75) with P value = 0.891.There was no statistically significantdifference as regards interleukin-6 polymorphism at position (−174 G/C), interleukin-10 polymorphism at position (-1082G/A) between inhibitor positive and inhibitor negative patients. Conclusion: There was no relation between interleukin-6 polymorphism at position (−174 G/C) , interleukin-10 polymorphism at position (-1082G/A)and the development of factor VIII inhibitors in patients with hemophilia A despite of the high frequency of G allele among inhibitors corresponding to the previous studies done . Further studies are recommended with larger cohort and other SNPs. Disclosures Hassab: Global Blood Therapeutics: Research Funding.

Sign in / Sign up

Export Citation Format

Share Document